Status:

COMPLETED

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)

Lead Sponsor:

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Conditions:

Advanced Solid Tumor

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The study was conducted in two periods, Period 1 (mass balance) and Period 2 (extension). The purpose of Period 1 of this study was to provide a quantitative characterization of the mass balance, rate...

Eligibility Criteria

Inclusion

  • .
  • Histologically proven advanced solid tumors that are considered appropriate for treatment in Period 2 of this study, for which no effective standard therapy exists, or standard therapy has failed or cannot be tolerated
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) =\< 1
  • Evaluable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) at Screening
  • Participant has adequate renal, hematological and hepatic function
  • Other protocol defined inclusion criteria could apply

Exclusion

  • Participants with uncontrolled intercurrent illness including, but not limited to, severe active infection including, acute respiratory syndrome coronavirus-2 infection/coronavirus disease 2019 (Covid 19), immune deficiencies, uncontrolled diabetes, uncontrolled arterial hypertension and symptomatic congestive heart failure
  • Concurrent participation in another interventional clinical study is not permitted.
  • Known hypersensitivity to the study interventions, a similar structural compound, or to one or more excipients used
  • Prior or concurrent treatment with a nonpermitted drug/intervention from the first dose of study intervention administration, as defined per protocol.
  • Other protocol defined exclusion criteria could apply

Key Trial Info

Start Date :

February 15 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 28 2023

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT05246111

Start Date

February 15 2022

End Date

June 28 2023

Last Update

November 22 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Magyar Honvédség Egészségügyi Központ, Podmaniczky utcai telephely, Onkológiai Osztály

Budapest, Hungary

2

PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely

Budapest, Hungary

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208) | DecenTrialz